OHSU

IRB #

IRB00009365

Title

An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to compare the effects, good and/or bad, of AGS-003, the study drug, plus regular treatment against regular treatment alone on kidney cancer to find out which is better.

Medical Condition(s)

Kidney Cancer

Eligibility Criteria

*Must be 18 years or older
* Subjects must have a confirmed diagnosis of kidney cancer
*Will have or have scheduled surgery to remove your kidney cancer
* Subject must not have prior anti-cancer treatment expect for a planned full or partial surgical removal of the affected kidney(s).
* Subject's medical history will be reviewed in detail for study eligibility.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

At least 3 years

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Argos Therapeutics, Inc

Recruitment End

01/30/2015

Compensation Provided

No


Go Back